Benzinga | Jun 24, 2021 07:14AM EDT

SVB Leerink Upgrades Intersect ENT to Outperform, Raises Price Target to $23

SVB Leerink analyst Richard Newitter upgrades Intersect ENT (NASDAQ:XENT) from Market Perform to Outperform and raises the price target from $21 to $23.